miR-223 may be a key onco-miRNA modulating the sensitivity of NSCLC cells to erlotinib by inhibiting FBXW7 but not IGF1R. Moreover, the Notch/miR-223/FBXW7 pathway represents a promising therapeutic target for NSCLC patients whose tumors are resistant to erlotinib. This evidence concerns the gene FBXW7 and non-small cell lung carcinoma.